BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18598723)

  • 1. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein.
    Wang R; Song A; Levin J; Dennis D; Zhang NJ; Yoshida H; Koriazova L; Madura L; Shapiro L; Matsumoto A; Yoshida H; Mikayama T; Kubo RT; Sarawar S; Cheroutre H; Kato S
    Antiviral Res; 2008 Nov; 80(2):168-77. PubMed ID: 18598723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
    Liu W; Zou P; Chen YH
    Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells.
    Wang Y; Zhou L; Shi H; Xu H; Yao H; Xi XG; Toyoda T; Wang X; Wang T
    Biochem Biophys Res Commun; 2009 Jul; 385(1):118-22. PubMed ID: 19410554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection.
    Zou P; Liu W; Chen YH
    Int Immunopharmacol; 2005 Apr; 5(4):631-5. PubMed ID: 15710332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates.
    Song A; Myojo K; Laudenslager J; Harada D; Miura T; Suzuki K; Kuni-Kamochi R; Soloff R; Ohgami K; Kanda Y
    Antiviral Res; 2014 Nov; 111():60-8. PubMed ID: 25218949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus.
    Zhang M; Zharikova D; Mozdzanowska K; Otvos L; Gerhard W
    Mol Immunol; 2006 Jul; 43(14):2195-206. PubMed ID: 16472860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Universal influenza A vaccine: optimization of M2-based constructs.
    De Filette M; Min Jou W; Birkett A; Lyons K; Schultz B; Tonkyro A; Resch S; Fiers W
    Virology; 2005 Jun; 337(1):149-61. PubMed ID: 15914228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A humanized anti-M2 scFv shows protective in vitro activity against influenza.
    Gabbard J; Velappan N; Di Niro R; Schmidt J; Jones CA; Tompkins SM; Bradbury AR
    Protein Eng Des Sel; 2009 Mar; 22(3):189-98. PubMed ID: 19054791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A "universal" human influenza A vaccine.
    Fiers W; De Filette M; Birkett A; Neirynck S; Min Jou W
    Virus Res; 2004 Jul; 103(1-2):173-6. PubMed ID: 15163506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a fully human monoclonal antibody against extracellular domain of matrix protein 2 of influenza A virus.
    Ozawa T; Jin A; Tajiri K; Takemoto M; Okuda T; Shiraki K; Kishi H; Muraguchi A
    Antiviral Res; 2011 Sep; 91(3):283-7. PubMed ID: 21726583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.
    Zharikova D; Mozdzanowska K; Feng J; Zhang M; Gerhard W
    J Virol; 2005 Jun; 79(11):6644-54. PubMed ID: 15890902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
    Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
    J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human single chain monoclonal antibody that recognizes matrix protein of heterologous influenza A virus subtypes.
    Poungpair O; Chaicumpa W; Kulkeaw K; Maneewatch S; Thueng-in K; Srimanote P; Tongtawe P; Songserm T; Lekcharoensuk P; Tapchaisri P
    J Virol Methods; 2009 Jul; 159(1):105-11. PubMed ID: 19442853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1.
    Maneewatch S; Thanongsaksrikul J; Songserm T; Thueng-In K; Kulkeaw K; Thathaisong U; Srimanote P; Tongtawe P; Tapchaisri P; Chaicumpa W
    Antivir Ther; 2009; 14(2):221-30. PubMed ID: 19430097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
    Mozdzanowska K; Maiese K; Furchner M; Gerhard W
    Virology; 1999 Feb; 254(1):138-46. PubMed ID: 9927581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.